New steroids and steroid–longacting β2agonist combinations: Expert Opinion on Therapeutic Patents: Vol 13, No 4

Views

CrossRef citations to date

Altmetric

Abstract

New, highly selective, glucocorticoid receptor agonists based on an androstane 17β-carbothioate ester scaffold are claimed. Combinations of these steroids with novel long-acting β₂ agonists are also claimed. This patent defines potential replacements for fluticasone propionate and the combination of salmeterol and fluticasone propionate (Advair™, Glaxo Wellcome, Inc.).

Keywords

Reprints and Corporate Permissions

Please note: Selecting permissions does not provide access to the full text of the article, please see our help page How do I view content?

To request a reprint or corporate permissions for this article, please click on the relevant link below:

Order Reprints Request Corporate Permissions

Academic Permissions

Please note: Selecting permissions does not provide access to the full text of the article, please see our help page How do I view content?

Obtain permissions instantly via Rightslink by clicking on the button below:

Request Academic Permissions

If you are unable to obtain permissions via Rightslink, please complete and submit this Permissions form. For more information, please visit our Permissions help page.

New steroids and steroid–longacting β₂agonist combinations

Information for

Open access

Opportunities

Help and information

New steroids and steroid–longacting β2agonist combinations

Abstract

Reprints and Corporate Permissions

Academic Permissions

Related research

To cite this article:

Download citation

Information for

Open access

Opportunities

Help and information

Keep up to date

Your download is now in progress and you may close this window

Login or register to access this feature

New steroids and steroid–longacting β₂agonist combinations